Corporate News - Archive 2026

Beauty segment: profitability again significantly increased

  • Revenue: +5.7% to EUR 27.1 million (Q1 2025: EUR 25.6 million)
  • EBIT: +37.6% to EUR 9.2 million (Q1 2025: EUR 6.7 million)
  • EBIT margin: 33.9% (Q1 2025: 26.0%)

Group figures: shaped by the sale of HAEMATO Pharm GmbH

  • Group revenue: EUR 46.8 million (Q1 2025: EUR 92.7 million)
  • EBIT: EUR 5.0 million (Q1 2025: EUR 8.8 million)

| Investor News

M1 Kliniken AG (ISIN DE000A0STSQ8) has cancelled the treasury shares acquired under its share buyback programme and reduced its share capital accordingly.

On 25 March 2026, the Management Board resolved, with the approval of the Supervisory Board granted on 26 March 2026 and on the basis of the authorisation by the Annual General Meeting of 17 July 2024, to reduce the Company's share capital by EUR 1,088,289 from EUR 19,643,403 to EUR 18,555,114. The capital reduction became effective upon registration in the commercial register of the Local Court of Charlottenburg (HRB 107637 B) on 26 May 2026.

| Investor News

Group key figures at a glance

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Ad-hoc news

At today's balance sheet meeting, the Supervisory Board of M1 Kliniken AG (ISIN: DE000A0STSQ8) approved the annual financial statements and the consolidated financial statements of the Company for the 2025 financial year, as submitted by the Management Board, in accordance with §§ 171, 172 AktG. The annual financial statements are thereby adopted pursuant to § 172 AktG.

The Supervisory Board and the Management Board today resolved to propose to the Annual General Meeting a dividend of EUR 1.20 per dividend-bearing share.

The 2025 Annual Report of M1 Kliniken AG is expected to be published on 20 May 2026.

| Investor News

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.